Disappointingly, no responses to binimetinib were observed in patients with colorectal cancer in either the KRAS- or BRAF-mutant cohorts; this result is consistent with other single-agent clinical studies of MEK inhibitors in patients with colorectal cancer (Rinehart et al, 2004; Zimmer et al, 2014) and suggests combination therapy may be needed to treat this tumour type. This evidence concerns the gene MAP2K7 and neoplasm.